LLY · News · 20260824N
Litigation - Retatrutide Black Market
ELI LILLY & Co · 2026-08-24 · Importance 31 · Surprise 42 · In source text
Eli Lilly sued six companies for allegedly selling unapproved, black-market versions of retatrutide, an experimental obesity medicine. Retatrutide remained in Phase 3 clinical trials and had not received regulatory approval as of August 24, 2026. The litigation seeks to protect the commercial value and regulatory position of Lilly’s pipeline asset amid reported demand for unauthorized weight-loss products.
Key facts
- Eli Lilly is suing six companies for illegally selling black-market versions of retatrutide, an experimental obesity drug still in Phase 3 trials and not yet approved. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Eli Lilly is suing six companies for illegally selling black-market versions of retatrutide, an experimental obesity drug still in Phase 3… |